Cocaine and Butyrylcholinesterase Gene Therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter briefly describes the promise of mutated versions of butyrylcholinesterase (BChE), a metabolic enzyme altered to treat cocaine addiction. BChE has been engineered into a highly efficient cocaine hydrolase (CocH) that inactivates cocaine within seconds after its appearance in the bloodstream, thus barring drug access to brain reward centers. Studies in rodent models have shown that CocH not only prevents cocaine's stimulant and rewarding effects but also averts seizures and death from normally lethal cocaine overdoses. CocH expressed by adenoviral gene transfer vector enables durable and effective levels of enzyme expression in liver and plasma. Recent efforts at the Mayo Clinic are focusing on accumulating preclinical evidence of safety and, ultimately, advancing this therapy into human trials.

Original languageEnglish (US)
Title of host publicationThe Neuroscience of Cocaine
Subtitle of host publicationMechanisms and Treatment
PublisherElsevier Inc.
Pages673-678
Number of pages6
ISBN (Electronic)9780128037928
ISBN (Print)9780128037508
DOIs
StatePublished - May 16 2017

    Fingerprint

Keywords

  • Butyrylcholinesterase
  • Cocaine hydrolase
  • Gene transfer vectors

ASJC Scopus subject areas

  • Psychology(all)

Cite this

Murthy, V., & Brimijoin, W. S. (2017). Cocaine and Butyrylcholinesterase Gene Therapy. In The Neuroscience of Cocaine: Mechanisms and Treatment (pp. 673-678). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-803750-8.00068-3